Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831 clinical trials
Also written ACE1831.
Its developmentBy Acepodia Biotech, step by step2 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ACE1831
- 3
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Acepodia Biotech, Inc. (2) · Tongji Hospital (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831.
- Oct 2027ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (SLE)Not applicable · Tongji Hospital
Studies
Open first, then newest update. How each study uses Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (SLE)Not yet recruitingNot applicableTongji HospitalNCT07314567Written as ACE1831How we know
- Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseActive, not recruitingPhase 1/2Acepodia Biotech, Inc.NCT07061938Written as ACE1831How we know
- ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesCompletedPhase 1Acepodia Biotech, Inc.NCT05653271Written as ACE1831How we know